From: Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma
Characteristics | Â | Cancer subgroups | |||||||
---|---|---|---|---|---|---|---|---|---|
No cancer (n = 2,023) | Total (N = 154) | Breast (n = 65) | Lung (n = 16) | Haemato (n = 19) | GI (n = 17) | GU (n = 6) | Gynae (n = 17) | Skin (n = 6) | |
Sex | |||||||||
Female, n (%) | 1,663 (82.2) | 131 (85.1) | 65 (100) | 12 (75) | 14 (73.7) | 13 (76.5) | 2 (33.3) | 17 (100) | 3 (50) |
Male, n (%) | 360 (17.8) | 23 (14.9) | NA | 4 (25) | 5 (26.3) | 4 (23.5) | 4 (66.7) | NA | 3 (50) |
SSc/cancer onset | |||||||||
Median age (±SD) at SSc onset, years | 45 (±14.1) | 53 (±11.9) | 53 (±11.1) | 47 (±19.5) | 51.5 (±9.4) | 53 (±11.4) | 59 (±18.4) | 53 (±23.7) | 59.5 (±19.1) |
IQR = 35 to 55 | IQR = 43 to 58 | IQR = 44 to 58 | IQR = 41 to 54 | IQR = 44 to 56 | IQR = 45 to 60 | IQR39 to 68 | IQR = 35 to 57 | IQR = 46 to 63 | |
Cancer prior to SSc onset (median ± SD), months | No cancer | 39.5 (±81.6) | 36 (±77.3) | NA | 109 (±88.2) | 8.5 (±27.7) | 25 (±74.4) | 141 (±104.8) | NA |
IQR = 12 to 125 | IQR = 11 to 114 | IQR = 29 to 190 | IQR = 1 to 48 | IQR = 4 | IQR = 25 to 243 | ||||
Cancer after SSc onset, (median ± SD), months | No cancer | 119 (±95.3) | 108 (±108.5) | 125 (±93.8) | 101 (±73.4) | 168 (±90.6) | 116.5 (±79.9) | 137 (±91.9) | 62 (±55.5) |
IQR = 41 to 185 | IQR = 25 to 209 | IQR = 71 to 200 | IQR = 20 to 161 | IQR = 119 to 233 | IQR = 60 | IQR = 20 to 194 | IQR = 23 to 125 | ||
SSc subsets | |||||||||
dcSSc, n (%) | 657 (32.5) | 53 (34.4) | 22 (33.8) | 5 (31.3) | 8 (42.1) | 4 (23.5) | 2 (33.3) | 4 (23.5) | 3 (50) |
lcSSc, n (%) | 1,260 (62.3) | 98 (63.6) | 42 (64.6) | 11 (68.8) | 11 (57.9) | 12 (70.6) | 3 (50) | 13 (76.5) | 3 (50) |
Missing cases, n (%) | 106 (5.2) | 3 (1.9) | 1 (1.5) | 0 (0) | 0 (0) | 1 (5.9) | 1 (16.7) | 0 (0) | 0 (0) |
SSc autoantibody status | |||||||||
ACA, n (%) | 550 (27.2) | 40 (26) | 17 (26.2) | 2 (12.5) | 4 (21.1) | 8 (47.1) | 1 (16.7) | 6 (35.3) | 1 (16.7) |
Scl to 70, n (%) | 416 (20.6) | 28 (18.2) | 10 (15.4) | 5 (31.3) | 5 (26.3) | 1 (5.9) | 1 (16.7) | 4 (23.5) | 1 (16.7) |
RNAP, n (%) | 247 (12.2) | 41 (26.6) | 19 (29.2) | 4 (25) | 5 (26.3) | 3 (17.6) | 2 (33.3) | 3 (17.6) | 3 (50) |
Others, n (%) | 515 (25.4) | 31 (20) | 13 (19.9) | 3 (18.9) | 4 (21) | 3 (17.6) | 1 (16.7) | 4 (23.6) | 1 (16.7) |
ANA-negative, n (%) | 75 (3.7) | 9 (5.8) | 4 (6.2) | 0 (0) | 1 (5.3) | 2 (11.8) | 1 (16.7) | 0 (0) | 0 (0) |
Missing cases, n (%) | 220 (10.9) | 5 (3.2) | 2 (3.1) | 2 (12.5) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
Organ involvementb | |||||||||
Lung fibrosis, n (%) | NA | 52 (33.8) | 24 (36.9) | 8 (50) | 6 (31.6) | 4 (23.5) | 3 (33.3) | 2 (11.8) | 2 (33.3) |
PAH, n (%) | NA | 27 (17.5) | 15 (23.1) | 1 (6.3) | 3 (15.8) | 3 (17.6) | 0 (0) | 2 (11.8) | 1 (16.7) |
GI, n (%) | NA | 85 (55.2) | 35 (53.8) | 9 (56.3) | 12 (63.2) | 9 (52.9) | 1 (16.7) | 10 (58.8) | 3 (50) |
SRC, n (%) | NA | 16 (10.4) | 4 (6.2) | 1 (6.3) | 2 (10.5) | 4 (23.5) | 1 (16.7) | 2 (11.8) | 0 (0) |